Table 2.

Baseline HPV seropositivity and subsequent risk of corresponding oral HPV infection for HPV types 16, 33, and 45.

	Oral HPV incidence
Measure*	Participants	Oral HPV Infections	Person-time (person- years)	Incidence Rate (infs/100 p-ys)	Unadjusted HR#	Adjusted HR^#
HPV 16 L1 seropositive
No	606	16	1459	1.10	REF	REF
Yes	183	7	427	1.64	1.4 (0.59–3.3)	1.1 (0.41–3.0)
HPV 33 L1 seropositive
No	510	10	1286	0.78	REF	REF
Yes	279	1	706	0.14	0.18 (0.02–1.4)	0.11 (0.01–0.78)
HPV 45 L1 seropositive
No	558	8	1422	0.56	REF	REF
Yes	232	11	578	1.90	3.4 (1.3–8.4)	3.6 (1.1–11.8)

^{^}Adjusted for age, gender, smoking status, number of recent and lifetime oral sex partners, HIV/CD4 status, study site, and frequency of recent toothbrushing

^*Seropositivity measured via the ELISAs optical density values

^#Seropositivity’s effect on subsequent hazard of corresponding oral HPV infection was measured through the Wei-Lin-Weissfeld method